FY2029 EPS Estimate for Altimmune Decreased by Analyst

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Analysts at HC Wainwright lowered their FY2029 EPS estimates for shares of Altimmune in a research note issued on Thursday, May 22nd. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of $1.22 for the year, down from their previous estimate of $1.26. HC Wainwright has a "Buy" rating and a $12.00 price objective on the stock. The consensus estimate for Altimmune's current full-year earnings is ($1.35) per share.

ALT has been the subject of several other research reports. Wall Street Zen raised Altimmune from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. William Blair restated a "market perform" rating on shares of Altimmune in a report on Friday, March 14th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $20.20.

Altimmune Stock Down 0.6%

Altimmune stock traded down $0.04 during trading hours on Monday, reaching $5.57. 347,336 shares of the company's stock were exchanged, compared to its average volume of 2,384,309. The firm has a market capitalization of $452.09 million, a PE ratio of -3.58 and a beta of 1.13. The firm's 50 day simple moving average is $5.09 and its 200 day simple moving average is $6.47. Altimmune has a twelve month low of $3.55 and a twelve month high of $11.16.

Altimmune (NASDAQ:ALT - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.09. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same quarter last year, the firm earned ($0.34) earnings per share.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ALT. GAMMA Investing LLC increased its position in shares of Altimmune by 214.2% during the first quarter. GAMMA Investing LLC now owns 6,745 shares of the company's stock worth $34,000 after acquiring an additional 4,598 shares in the last quarter. SBI Securities Co. Ltd. acquired a new position in Altimmune during the 4th quarter valued at about $45,000. Magnus Financial Group LLC bought a new stake in Altimmune during the 1st quarter worth approximately $50,000. Headland Capital LLC purchased a new stake in shares of Altimmune in the first quarter worth approximately $50,000. Finally, Geneos Wealth Management Inc. purchased a new stake in shares of Altimmune in the first quarter worth approximately $50,000. 78.05% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Altimmune news, CFO Gregory L. Weaver purchased 10,000 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was acquired at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the purchase, the chief financial officer now owns 10,000 shares of the company's stock, valued at $52,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.10% of the company's stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.